Disclosure of payments made to HCPs in the UK
Cooperation between pharmaceutical companies, regulators, Healthcare Professionals (HCPs), Healthcare Organisations (HCOs) and patients, is essential for the sustainable improvement of healthcare. These relationships have helped deliver numerous innovative new medicines and changed the way many diseases impact on our lives. HCPs have always been and will always remain valuable partners for GSK.
As experts in their field, they provide us with first hand scientific and medical knowledge and unique insights into patient care. This partnership is fundamental to the progression of medical science, helping to meet disparate patient and public health needs.
Under the EFPIA Disclosure Code, from 2016 EFPIA member companies pledged to disclose the transfers of value they make to HCPs and HCOs in connection with prescription medicines, on an individual named basis (aggregate by exception only). This includes, for example, sponsorship for travel and registration fees to attend medical congresses, HCP consultancy fees for speaker arrangements or for chairing meetings and grants to HCOs. Transfers of value made to HCPs and HCOs for activities related to research and development are disclosed as an aggregate number.
In line with the EFPIA Disclosure Code, disclosure information in the UK is published annually (covering the previous year) through the ABPI Disclosure UK website: www.disclosureuk.org.uk
Media enquiries: please contact the UK Pharma Communications Team on +44 208 990 2144.